BETAPACE AF Rx
Generic Name and Formulations:
Sotalol HCl 80mg, 120mg, 160mg; scored tabs.
Indications for BETAPACE AF:
Maintenance of normal sinus rhythm in patients with highly symptomatic atrial fibrillation or atrial flutter who are currently in sinus rhythm.
Initiate only in appropriate clinical setting that can provide continuous ECG, creatinine clearance monitoring, and cardiac resuscitation. If QT ≤450msec and CrCl>60mL/min: initially 80mg twice daily. Renal impairment (CrCl 40–60mg/mL): initially 80mg once daily; <40mL/min: see Contraindications. See literature for dose titration and required monitoring.
Sinus bradycardia (<50bpm). Sick sinus syndrome. 2nd or 3rd degree AV block, unless paced. Baseline QT interval >450msec. Long QT syndromes. Cardiogenic shock. Uncontrolled heart failure (patients with NYHA Class IV may not tolerate beta-blockade; titrate slowly and give full support if attempting to use sotalol in these patients). Renal impairment (CrCl<40mL/min). Hypokalemia (<4mEq/L). Asthma.
Not for use in easily-reversible AFIB/AFL. Do not use for asymptomatic atrial fibrillation/flutter. Do not substitute for Betapace. Increased arrhythmia risk in females, renal impairment, excessive QTc prolongation, history of cardiomegaly or CHF, sustained ventricular tachycardia, electrolyte disturbances, or with high doses of sotalol. Reduce dose or discontinue if QT interval ≥500msec occurs. Correct electrolyte imbalances (esp. hypokalemia, hypomagnesemia) before starting sotalol. Bronchospastic disease. CHF. Left ventricular dysfunction. Diabetes. Acid-base imbalance. Avoid abrupt cessation (withdraw over 1–2 weeks if possible, monitor for angina and acute coronary insufficiency). Hyperthyroidism. Surgery. Pregnancy (Cat.B). Nursing mothers: not recommended.
Class IA antiarrhythmics (eg, disopyramide, quinidine, procainamide), Class III antiarrhythmics (eg, amiodarone), or other drugs that prolong QT interval (eg, some phenothiazines, cisapride, bepridil, tricyclic antidepressants, macrolides): not recommended. Withhold Class I and III antiarrhythmics for at least 3 half-lives before starting sotalol. Caution with Class IB and IC antiarrhythmics. Additive conduction abnormalities and hypotension with digitalis, β-blockers, calcium channel blockers. Hypotension, bradycardia with reserpine, guanethidine, other catecholamine-depleting drugs. Increased rebound hypertension when withdrawing clonidine. Diuretics (monitor electrolytes). Antagonizes albuterol, other β-agonists. Monitor antidiabetic agents. May block epinephrine. Avoid within 2 hours of aluminum- or magnesium-containing antacids.
Class II and III antiarrhythmic.
Fatigue, dizziness, bradycardia, new or exacerbated arrhythmias (eg, torsade de pointes), dyspnea, ECG abnormalities, GI or visual disturbances, headache, insomnia.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Predicting Seizure Risk Following Ischemic Stroke With SeLECT Score
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Exome-Targeted Capture Sequencing Can Diagnose Previously-Undetected Ataxia
- Strategies for Preventing and Treating Delirium
- High Total Cholesterol Neuroprotective Against Cognitive Decline